Silexion Therapeutics Files 8-K
Ticker: SLXNW · Form: 8-K · Filed: Sep 11, 2025 · CIK: 2022416
Sentiment: neutral
Topics: corporate-filing, regulation-fd, financial-statements
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (SLXN) filed an 8-K on 9/11/25, check for updates.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) filed an 8-K on September 11, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporated in the Cayman Islands, is based in Ramat-Gan, Israel, and trades on NASDAQ under the ticker SLXN.
Why It Matters
This filing indicates ongoing corporate reporting and potential updates regarding financial statements or material events for Silexion Therapeutics Corp.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain immediately material adverse information.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- September 11, 2025 (date) — Date of report
- NASDAQ (company) — Exchange traded on
- SLXN (ticker) — Trading symbol
FAQ
What is the primary purpose of this 8-K filing?
The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting under Regulation FD and including financial statements and exhibits.
When was Silexion Therapeutics Corp. formerly known as?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences, with a name change date of May 6, 2024.
Where is Silexion Therapeutics Corp. headquartered?
The company's principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
On which exchange does Silexion Therapeutics Corp. trade?
The company trades on NASDAQ.
What is the filing date of this 8-K report?
The report was filed as of September 11, 2025.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-09-11 07:31:22
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
Filing Documents
- zk2533776.htm (8-K) — 48KB
- exhibit_99-1.htm (EX-99.1) — 19KB
- image00001.jpg (GRAPHIC) — 27KB
- image2.jpg (GRAPHIC) — 1KB
- image00003.jpg (GRAPHIC) — 37KB
- 0001178913-25-003292.txt ( ) — 331KB
- slxn-20250911.xsd (EX-101.SCH) — 5KB
- slxn-20250911_def.xml (EX-101.DEF) — 18KB
- slxn-20250911_lab.xml (EX-101.LAB) — 27KB
- slxn-20250911_pre.xml (EX-101.PRE) — 20KB
- zk2533776_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 11, 2025, Silexion Therapeutics Corp issued a press release entitled "Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration." A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated September 11, 2025 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: September 11, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer